



European College of
Neuropsychopharmacology

Annual Report 2024

European College of Neuropsychopharmacology

Annual Report 2024

1. About ECNP	3
Objectives	3
Executive Committee	3
2. Activities 2024	5
Promoting and disseminating science	5
Fostering talent	6
Public outreach	6
3. Financial Overview	7
Financial statements	8
4. Future Outlook	10



The European College of Neuropsychopharmacology is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

1. About ECNP

ECNP is an independent European scientific association dedicated to ensuring that advances in the understanding of brain function and human behaviour are translated into better treatments and enhanced public health.

The mission of ECNP is to advance the science of the brain, promote better treatment and enhance brain health. It is non-profit-making.

Address:	Daltonlaan 400, 3584 BK Utrecht
E-mail:	secretariat@ecnp.eu
Website:	https://www.ecnp.eu
RSIN:	823523974
Dutch TAX number:	NL 823523974B01
ANBI:	The European College of Neuropsychopharmacology is a public-interest-serving entity (<i>algemeen nut beogende instelling</i> – ANBI) under Dutch tax law.

The European College of Neuropsychopharmacology is referred to hereafter as 'ECNP' or 'the College'.

Objectives

ECNP was founded in 1987 to stimulate high-quality experimental and clinical research in applied and translational neuroscience, with a view to advancing the development of better treatments for those suffering from disorders of the brain.

ECNP seeks to bring together all those involved in or interested in the scientific study of applied and translational neuroscience by arranging scientific meetings, educational activities, research networks, and publishing and disseminating scientific research; to offer guidance and information to the scientific community and other relevant stakeholders on matters pertaining to applied and translational neuroscience; and to provide a format for coordination and for development of common standards in Europe.

Executive Committee

Officers

Martien Kas
President
University of Groningen
The Netherlands

Andreas Reif
President-Elect
University Hospital Frankfurt
Germany

Elisabeth Binder
Vice-President
Max Planck Institute of Psychiatry
Munich, Germany

Suzanne Dickson
Secretary
University of Gothenburg
Sweden

Gitte Moos Knudsen
Past-President
Copenhagen University Hospital
Denmark

Brenda Penninx
Treasurer
Amsterdam University Medical Center
The Netherlands

Councillors

David Baldwin
University of Southampton
United Kingdom

Iiris Hovatta
University of Helsinki
Finland

Paolo Brambilla
University of Milan
Italy

Marin Jukić
University of Belgrade
Serbia

Iria Grande
Hospital Clinic de Barcelona
Spain

Marion Leboyer
University of Paris Est Créteil
France

Co-opt member

Gerry-Dawson
P1vital, Ltd
Wallingford, United Kingdom

Ex officio members

John Cryan
Chair, Scientific Programme Committee
35th, 36th, 37th ECNP Congress
University College Cork
Ireland

Eduard Vieta
Editor-in-Chief, European
Neuropsychopharmacology
University of Barcelona
Spain

Andreas Meyer-Lindenberg
Editor-in-Chief, *Neuroscience Applied*
Central Institute of Mental Health (ZI)
Mannheim, Germany

Executive Director

Alexander Schubert

The members of the Executive Committee receive no remuneration for their role. The President receives € 15,000 per annum, payable to his institution, for secretarial assistance. Each Officer receives € 4,000 per annum, payable to his or her institution, for secretarial assistance. And each member of the Executive Committee is entitled to € 1,500 per annum to cover associated meeting costs, including ground transportation, lunch, dinner, drinks, etc.

2. ECNP Activities 2024

To execute its mission to support European applied and translational neuroscience, ECNP performs a number of activities annually, focusing especially on stimulating research, sponsoring education and raising awareness.

Promoting and disseminating science

- **European Neuropsychopharmacology**

ECNP publishes, in partnership with Elsevier B.V., the international peer-reviewed journal *European Neuropsychopharmacology*, featuring the latest in applied brain science across the spectrum of basic and clinical and research.

The 2024 impact factor is 6.100.

- **ECNP Networks and Thematic Working Groups (TWGs)**

These virtual, multi-centre European research clusters provide a unique platform for the collection and aggregation of continent-wide clinical data, in order to foster research collaboration and ideas-sharing across the translational neurosciences.

The 25 Networks and Thematic Working Groups collectively comprise one of ECNP's most far-reaching initiatives, bringing together several hundred of Europe's leading researchers in applied and translational neuroscience, and providing the springboard for some of the region's largest and most important projects in brain research.

- **The International Society for CNS Clinical Trials and Methodology (ISCTM)**

ISCTM is an independent organisation devoted to advancing clinical research methods related to the development and use of central nervous system (CNS) therapeutics. Every two years the ECNP-ISCTM joint meeting brings together international stakeholders in academia, industry, government, and the regulatory and payer communities to address strategic clinical, regulatory, methodological and policy challenges in CNS clinical research.

The next joint meeting will be on 10-11 October 2025 in Amsterdam, the Netherlands.

- **ECNP Neuropsychopharmacology Award**

This award, conferred annually, recognises exceptional research achievements in applied and translational neuroscience, alternating between basic and clinical science. The award comes with a prize of € 10,000, contingent upon publication of a review paper in *European Neuropsychopharmacology*.

Winner 2024: Elias Eriksson, Sweden (clinical)

Elias Eriksson delivered his award lecture, 'The efficacy and mechanisms of action of SSRIs – lessons learnt from premenstrual dysphoric disorder and depression', on 22 September 2025 at the 37th ECNP Congress in Milan.

- **ECNP Citation Prize**

Awarded to the most-cited research paper in the ECNP journal, *European Neuropsychopharmacology* (ENP) in the preceding two years, the award recognises and encourages impactful original research. Promoted by ECNP.

Winner 2024: Konstantinos Fountoulakis et al., 'Results of the COVID-19 mental health international for the general population (COMET-G) study', *Eur. Neuropsychopharmacol*, 54 (2022) 21-40.

Fostering talent

- **ECNP Early Career Academy**

The ECNP Early Career Academy (ECA) offers a range of benefits aimed at fostering connectivity between outstanding early career scientists, facilitating their sustained, career-long engagement in ECNP, and providing opportunities to amplify their contributions to applied neuroscience. Developed in 2023 for launch in 2024, the Academy will grow to 100 members over five years, with each member serving a five-year term.

- **ECNP Rising Star Award**

The ECNP Rising Star Award honours early career researchers in applied and translational neuroscience who have the potential to advance the science of treatment and prevention of brain disorders. Conferred for the first time in 2020, in 2021 the number of awards was doubled. The award comes with an unrestricted prize of € 2,000 for each winner.

Winners 2024: Cristiana Cruceanu, Sweden; Robert McCutcheon, United Kingdom.

Cristiana Cruceanu's award presentation, 'The placenta-brain axis: transmission of maternal inflammatory and stress response', as well as Robert McCutcheon's, 'Relapse in psychosis: definition, mechanism, and management', were delivered on 23 September 2024 at the 37th ECNP Congress in Milan.

- **ECNP Research Internship**

The ECNP Research Internship (ERI) offers 15 early career scientists the opportunity of a short two-week exploratory experience in another European country.

Public outreach

- **European Affairs**

ECNP collaborates with a number of European societies to build European research and clinical capacity and advance the interests of the neuroscience research and best-practices treatment in Europe.

- ALBA Network for diversity, equity and inclusion in neuroscience – supporter
- Biomedical Alliance in Europe – member
- European Brain Council (EBC) – founding member

- European Federation of Psychiatric Trainees (EFPT) – supporter
- Federation of European Neuroscience Societies (FENS) – founding member
- Expert Platform on Mental Health – Depression (EPD) – supporter
- Global Alliance of Mental Illness Advocacy Networks (GAMIAN-Europe) – member

3. Financial Overview

ECNP's funding derived from donations, journal royalties, membership dues and investment income.

Its policy was at all times to handle its disposable assets in a responsible and sustainable manner according to the following principles:

- Proactive tax and regulatory compliance
- Capital preservation, adhering to agreed levels
- Budgetary discipline
- Ongoing diversification of the revenue base

To give substance to this, ECNP invested in securities through an established asset manager according to a defensive mandate. Its goal was to preserve wealth and ensure the College could deliver its public-good activities, not to maximise return or to increase its capital base.

ECNP transferred all its duties, financial resources and investments to ECNP Association as of 31 December 2024.

Financial statements 2024

Balance sheet as at 31 December 2024

(after appropriation of profit/losses)

	31-12-2024		31-12-2023	
	€	€	€	€
ASSETS				
FIXED ASSETS				
Financial fixed assets				
Securities		-		15,400,194
CURRENT ASSETS				
Accounts receivable				
Debtors	-		4,083	
Taxes	-		18,185	
Other accounts receivable	-		134,645	
		-		156,913
Bank deposits		-		30,272
		-		187,185
		-		15,587,379

	31-12-2024		31-12-2023	
	€	€	€	€
EQUITY AND LIABILITIES				
EQUITY				
Other reserves		-		15,374,453
CURRENT LIABILITIES				
Trade creditors	-		28,011	
Other liabilities	-		184,915	
		-		212,926
		-		15,587,379

Statement of income and expenditure 2024

	Balance 2024	Balance 2023
	€	€
Income		
Membership fees	137,583	118,884
Royalties	137,662	133,145
Interest and similar income	103,947	2,249
Total income	379,192	254,278
Expenses		
Administration	365,395	374,038
Other expenses	454,256	476,212
Total expenses	819,651	850,250
Balance before financial expense	-440,459	-595,972
Interest and similar charges	-3,633	-4,509
Net result	-444,092	-600,481
Appropriation of result		
Other reserves	-444,092	-600,481

4. Future Outlook

In order to rationalise the ECNP structure and reduce complexity, risk and cost by centralising into one legal system, the General Assembly of Members voted in October 2023 to establish a Dutch Vereniging, ECNP Association. The Vereniging ECNP Association was accordingly incorporated in January 2024, with a view to continuing the activities currently conducted by ECNP. A Transfer of Property agreement was signed in September 2024 with the Property Components being, as of 31 December 2024, for the economic benefit, risk and account of ECNP Association. All future activities are with ECNP Association.

ECNP has permanently suspended its activities.



© 2025 European College of Neuropsychopharmacology

